Ainos (AIMD) 10-Q 16 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 01, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Trading Symbol	amar
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,144,810
Amendment Flag	false
Entity Central Index Key	1,014,763
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 264,184	$ 21,138
Prepaid expense and other current assets	1,977	18,154
Total current assets	266,161	39,292
Patents, net	76,962	72,105
Property and equipment, net	5,468	5,798
Total assets	348,591	117,195
Current liabilities:
Accounts payable and accrued expenses	86,252	58,550
Accrued interest - related parties	2,041	1,706
Accounts payable - related parties	75,000	144,426
Notes payable – related parties	384,555	384,555
Convertible note payable – related party	144,426
Total current liabilities	692,274	589,237
Total liabilities	$ 692,274	$ 589,237
Commitments and contingencies
Authorized shares - 10,000,000
Issued and outstanding shares – 0 at March 31, 2016 and December 31, 2015
Authorized shares - 100,000,000
Issued and outstanding shares – 20,144,810 at March 31, 2016 and December 31, 2015	$ 201,448	$ 201,448
Additional paid-in capital	173,128	(76,872)
Accumulated deficit	(718,259)	(596,618)
Total stockholders' deficit	(343,683)	(472,042)
Total liabilities and stockholders’ deficit	$ 348,591	$ 117,195

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred Stock, Par Value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Outstanding Shares	20,144,810	20,144,810
Common Stock, Par Value (in Dollars per share)	$ 0.01	$ 0.01

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Sales – Herbs	$ 4,400	$ 0
Total revenues	4,400	0
Cost of revenues:
Product sales	5,100	0
Total cost of revenues	5,100	0
Gross margin	(700)	0
Operating expenses:
Research and development expenses	0	0
Selling, general and administrative expenses	120,579	111,818
Total operating expenses	120,579	111,818
Operating loss	(121,279)	(111,818)
Other income (expense):
Interest expense	(362)	(271)
Net loss	(121,641)	(112,089)
Net loss applicable to common shareholders	$ (121,641)	$ (112,089)
Basic and diluted net loss per average share available to common shareholders (in Dollars per share)	$ (0.01)	$ (0.01)
Weighted average common shares outstanding – basic and diluted (in Shares)	20,144,810	20,144,810

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net cash provided by (used in) operating activities:	$ 1,663	$ (73,011)
Cash flows from investing activities:
Investment in equipment	0	(6,140)
Investment in patents	(8,617)	(58)
Net cash used in investing activities	(8,617)	(6,198)
Cash flows from financing activities:
Proceeds from private placement offering	250,000	0
Net cash provided by financing activities	250,000	0
Net change in cash	243,046	(79,209)
Cash and cash equivalents at beginning of period	21,138	318,556
Cash and cash equivalents at end of period	264,184	239,347
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Noncash transactions:
Conversion of accounts payable – related party to convertible note payable – related party	$ 144,426	$ 0

Note 1 - Organization and Busin

Note 1 - Organization and Business	3 Months Ended
	Mar. 31, 2016
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business. Amarillo Biosciences, Inc. (the "Company” or “Amarillo” or “ABI”), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases. The Company’s current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. In addition to the above core technology ABI is exploring the possibility of instituting new revenue streams along with the core technology thus expanding the Company’s current focus into a diversified business portfolio .

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	2. Basis of presentation. The accompanying financial statements, which should be read in conjunction with the financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission, are unaudited, but have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016.

Note 3 - Financial Condition

Note 3 - Financial Condition	3 Months Ended
	Mar. 31, 2016
Financial Condition [Abstract]
Financial Condition [Text Block]	3. Financial Condition. These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability. The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

Note 4 - Common Stock

Note 4 - Common Stock	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	4. Common Stock. The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On March 31, 2016, a total of 21,013,057 shares of common stock were either outstanding (20,144,810) or reserved for issuance upon exercise of options (8,568) or conversion of convertible debt to stock (859,679). No common stock was issued in the three months ending March 31, 2016. During the period ended March 31, 2016, the Company has received $250,000 for the purchase of 1,333,333 shares of common stock from Dr. Stephen T. Chen in connection with a $937,500 Private Placement Common Stock Security Offering. The offering contemplates the sale of a maximum of 5,000,000 shares at a cost of $0.1875 per share. The required SEC Form D was filed on May 6, 2016. As of March 31, 2016, these shares have not been issued.

Note 5 - Common Stock and Warra

Note 5 - Common Stock and Warrants	3 Months Ended
	Mar. 31, 2016
Stock Option And Warrants [Abstract]
Stock Option And Warrants [Text Block]	5. Common Stock Options and Warrants. As of March 31, 2016 there were no shares reserved as unexercised warrants and 8,568 shares reserved as unexercised options. No options or warrants expired in the first three months of 2016. A summary of the Company’s stock option activity and related information for the period ended March 31, 2016 is as follows: Options Price Range Outstanding December 31, 2015 8,568 $ 0.95 Granted - - Cancelled/Expired - - Exercised - - Outstanding March 31, 2016 8,568 0.95 Exercisable March 31, 2016 8,568 $ 0.95 A summary of the Company’s stock warrant activity and related information for the period ended March 31, 2016: Warrants Price Range Outstanding December 31, 2015 - $ - Granted - - Cancelled/Expired - - Exercised - - Outstanding March 31, 2016 - - Exercisable March 31, 2016 - $ -

Note 6 - Notes Payable - Relate

Note 6 - Notes Payable - Related Party	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	6. Notes Payable – Related Party. March 31, 2016 December 31, 2015 Note payable – related party $ 234,555 $ 234,555 Note payable – related party 150,000 150,000 384,555 384,555 Less: current portion (384,555 ) (384,555 ) Notes payable – related party, long term $ - $ - On November 20, 2014, the Class Three Secured Claim of Yang was deemed allowed in the amount of $150,000, secured by the same assets that secured Yang’s prepetition secured claim (See Texas Financing Statement No. 13-0029795076). This claim bears interest at the Applicable Federal Rate, will be fully amortized and paid as follows: four (4) consecutive equal annual installments of combined principal and interest, beginning September 1, 2015, and continuing on the same date of each succeeding year until September 1, 2018, when the obligation is due and payable in full. The first payment was due on September 1, 2015, in the amount of $37,811 (principal and interest). To date, the payment has not been made and there has been no demand for the payment. ABI is discussing the exchange of some or all of this debt, principal and interest, for ABI Common stock, with the holders. As of March 31, 2016, the outstanding balance is $150,000. Subsequent to consummation of the Plan, The Yang Group provided $234,555 for post-reorganization financing. This is unsecured and draws interest at the short term Applicable Federal Rate. There has been no demand and the parties are contemplating the exchange of some or all of this debt for ABI Common stock. As of March 31, 2016, the outstanding balance is $234,555.

Note 7 - Convertible Note Payab

Note 7 - Convertible Note Payable - Related Party	3 Months Ended
	Mar. 31, 2016
Convertible Debt [Abstract]
Convertible Debt [Text Block]	7. Convertible Note Payable – Related Party. On July 31, 2015, two investors paid a total of $225,000 for their subscribed investment to the Yang Group for an investment in 1,200,000 shares of ABI common stock. The investors agreed to pay a premium of $0.07 per share over the original cost of the stock, which was $0.12 per share. The Company allocated $144,426 as an Accounts payable – related party to Dr. Chen for his previous advances to the Company through The Yang Group. The remaining $80,574 was recognized as “additional paid in capital” (APIC) during the year ended December 31, 2015. Shares Subscribed Purchase Price Purchase Premium Total 200,000 $ 24,071 $ 13,429 $ 37,500 1,000,000 120,355 67,145 187,500 1,200,000 $ 144,426 $ 80,574 225,000 Less: Due to Dr. Stephen Chen (144,426 ) Additional paid in capital $ 80,574 Subsequently, an offering of $1,000,000 of Convertible Notes was made with a conversion rate of $0.168 per share. The SEC Form D was filed on April 7, 2016, and the first sale was a Convertible Promissory Note for the face amount of $144,426 to Dr. Stephen Chen, who as consideration to the Company, forwent immediate collection of the $144,126 mentioned in the preceding paragraphs.

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. Related Party Transactions. Dr. Stephen T. Chen, Chairman, CEO and President, of the Company advanced $75,000 to the Company on a periodic basis between January 18, 2016 and March 18, 2016 to be used for general operations. The $75,000 was classified on the Balance Sheet as Accounts payable – related parties and has been paid back to Dr. Chen subsequent to March 31, 2016.

Note 9 - Corporate Governance a

Note 9 - Corporate Governance and Stock	3 Months Ended
	Mar. 31, 2016
Corporate Governance And Stock [Abstract]
Corporate Governance And Stock [Text Block]	9. Corporate Governance and Stock - A Special Shareholders Meeting was held July 10, 2015, at which time the Company’s Certificate of Formation and Bylaws were materially modified, in a manner affecting the Company’s voting common stock (the only class of the Company’s securities of which shares are currently issued and outstanding); and also affecting the Company’s authorized shares of preferred stock, issuable in series, of which no shares or series are currently issued and outstanding. The general effect of such modifications was as follows: a. Stockholder supermajority vote requirements were changed from 2/3 of the issued and outstanding shares entitled to vote on a matter, to 51% of the issued and outstanding shares entitled to vote on such matter, with such change additionally applying to each voting class or series where a class or series of shares is entitled to vote separately on a matter. This change would apply to all existing or future supermajority vote requirements under Texas law, including without limitation, votes on Fundamental Business Transactions, and/or Fundamental Actions, as such are defined in the Texas Business Organizations Code. b. Requirements for action by written consent of Stockholders in lieu of a meeting were changed, to permit actions to be taken by the written consent of Stockholders having at least the minimum number of votes that would be necessary to take the action that is the subject of the consent at a meeting, in which each holder entitled to vote on the action is present and votes, in lieu of requiring that the written consent be unanimous, as at present. c. The requirement for notice to directors of Special Directors Meetings was changed from 24 hours to 4 hours. Additionally, at the Special Shareholder Meeting of July 10, 2015, the following Board of Directors was elected: Stephen T. Chen, Paul Tibbits, Yasushi Chikagami, Dan Fisher, and Nick Moren. There is expected to be no continuing arrangement or understanding among the members or former members of The Yang Group and their associates with respect to the election of directors, or other matters, although the unallocated shares to be retained by The Yang Group will continue to be voted by Stephen T. Chen, Chairman, CEO and President of the Company, until such time as they are distributed.

Note 10 - Subsequent Event

Note 10 - Subsequent Event	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	10. Subsequent Event. On April 25, 2016, the Company sold 2,316,667 shares of common stock for total proceeds of $434,375 in connection with the Private Placement Common Stock Security Offering. These shares have not yet been issued.

Note 5 - Common Stock and War16

Note 5 - Common Stock and Warrants (Tables)	3 Months Ended
	Mar. 31, 2016
Employee Stock Option [Member]
Note 5 - Common Stock and Warrants (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Price Range Outstanding December 31, 2015 8,568 $ 0.95 Granted - - Cancelled/Expired - - Exercised - - Outstanding March 31, 2016 8,568 0.95 Exercisable March 31, 2016 8,568 $ 0.95
Stock Warrant [Member]
Note 5 - Common Stock and Warrants (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Warrants Price Range Outstanding December 31, 2015 - $ - Granted - - Cancelled/Expired - - Exercised - - Outstanding March 31, 2016 - - Exercisable March 31, 2016 - $ -

Note 6 - Notes Payable - Rela17

Note 6 - Notes Payable - Related Party (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Related Party Transactions [Table Text Block]	March 31, 2016 December 31, 2015 Note payable – related party $ 234,555 $ 234,555 Note payable – related party 150,000 150,000 384,555 384,555 Less: current portion (384,555 ) (384,555 ) Notes payable – related party, long term $ - $ -

Note 7 - Convertible Note Pay18

Note 7 - Convertible Note Payable - Related Party (Tables)	3 Months Ended
	Mar. 31, 2016
Convertible Debt [Abstract]
Convertible Debt [Table Text Block]	Shares Subscribed Purchase Price Purchase Premium Total 200,000 $ 24,071 $ 13,429 $ 37,500 1,000,000 120,355 67,145 187,500 1,200,000 $ 144,426 $ 80,574 225,000 Less: Due to Dr. Stephen Chen (144,426 ) Additional paid in capital $ 80,574

Note 4 - Common Stock (Details)

Note 4 - Common Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Note 4 - Common Stock (Details) [Line Items]
Common Stock, Shares Authorized	100,000,000		100,000,000
Common Stock, Shares Outstanding and Reserved	21,013,057
Common Stock, Shares, Outstanding	20,144,810		20,144,810
Stock Issued During Period, Shares, New Issues	0
Proceeds from Issuance of Private Placement (in Dollars)	$ 250,000	$ 0
Amount of Private Placement (in Dollars)	$ 937,500
Private Placement [Member]
Note 4 - Common Stock (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	0
Sale of Stock, Price Per Share (in Dollars per share)	$ 0.1875
Chief Executive Officer [Member]
Note 4 - Common Stock (Details) [Line Items]
Proceeds from Issuance of Private Placement (in Dollars)	$ 250,000
Shares Authorized During Period, Private Placement	1,333,333
Exercise of Options [Member]
Note 4 - Common Stock (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	8,568
Debt Convertible to Common Stock [Member]
Note 4 - Common Stock (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	859,679
Maximum [Member]
Note 4 - Common Stock (Details) [Line Items]
Shares Authorized During Period, Private Placement	5,000,000

Note 5 - Common Stock and War20

Note 5 - Common Stock and Warrants (Details) - shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Note 5 - Common Stock and Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	8,568	8,568
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0
Stock Warrant [Member]
Note 5 - Common Stock and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations	0

Note 5 - Common Stock and War21

Note 5 - Common Stock and Warrants (Details) - Stock Option Activity	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Stock Option Activity [Abstract]
Outstanding December 31, 2015 | shares	8,568
Outstanding December 31, 2015 | $ / shares	$ 0.95
Granted | shares	0
Granted | $ / shares	$ 0
Cancelled/Expired | shares	0
Cancelled/Expired | $ / shares	$ 0
Exercised | shares	0
Exercised | $ / shares	$ 0
Outstanding March 31, 2016 | shares	8,568
Outstanding March 31, 2016 | $ / shares	$ 0.95
Exercisable March 31, 2016 | shares	8,568
Exercisable March 31, 2016 | $ / shares	$ 0.95

Note 5 - Common Stock and War22

Note 5 - Common Stock and Warrants (Details) - Stock Warrant Activity	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Note 5 - Common Stock and Warrants (Details) - Stock Warrant Activity [Line Items]
Outstanding December 31, 2015 | shares	0
Granted | shares	0
Cancelled/Expired | shares	0
Exercised | shares	0
Outstanding March 31, 2016 | shares	0
Exercisable March 31, 2016 | shares	0
Weighted Average [Member]
Note 5 - Common Stock and Warrants (Details) - Stock Warrant Activity [Line Items]
Outstanding December 31, 2015 | $ / shares	$ 0
Granted | $ / shares	0
Cancelled/Expired | $ / shares	0
Exercised | $ / shares	0
Outstanding March 31, 2016 | $ / shares	0
Exercisable March 31, 2016 | $ / shares	$ 0

Note 6 - Notes Payable - Rela23

Note 6 - Notes Payable - Related Party (Details)	Sep. 01, 2015USD ($)	Nov. 21, 2014USD ($)	Nov. 20, 2014USD ($)	Mar. 18, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Note 6 - Notes Payable - Related Party (Details) [Line Items]
Notes Payable, Related Parties					$ 384,555	$ 384,555
Proceeds from Related Party Debt				$ 75,000
Chief Executive Officer [Member]
Note 6 - Notes Payable - Related Party (Details) [Line Items]
Number of Installments			4
Debt Instrument, Periodic Payment	$ 37,811
Proceeds from Related Party Debt		$ 234,555
Chief Executive Officer [Member] | Secured Debt [Member]
Note 6 - Notes Payable - Related Party (Details) [Line Items]
Notes Payable, Related Parties			$ 150,000		150,000	150,000
Chief Executive Officer [Member] | Unsecured Debt [Member]
Note 6 - Notes Payable - Related Party (Details) [Line Items]
Notes Payable, Related Parties					$ 234,555	$ 234,555

Note 6 - Notes Payable - Rela24

Note 6 - Notes Payable - Related Party (Details) - Related Party Transactions - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Nov. 20, 2014
Related Party Transaction [Line Items]
Note payable – related party	$ 384,555	$ 384,555
Less: current portion	(384,555)	(384,555)
Notes payable – related party, long term	0	0
Chief Executive Officer [Member] | Unsecured Debt [Member]
Related Party Transaction [Line Items]
Note payable – related party	234,555	234,555
Chief Executive Officer [Member] | Secured Debt [Member]
Related Party Transaction [Line Items]
Note payable – related party	$ 150,000	$ 150,000	$ 150,000

Note 7 - Convertible Note Pay25

Note 7 - Convertible Note Payable - Related Party (Details) - USD ($)	Jul. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Note 7 - Convertible Note Payable - Related Party (Details) [Line Items]
Payment Received from Investors as Payment of a Subscribed Investment	$ 225,000			$ 225,000
Common Stock, Shares Subscribed but Unissued (in Shares)	1,200,000			1,200,000
Premium Over the Price of Stock Price (in Dollars per share)	$ 0.07
Shares Issued, Price Per Share (in Dollars per share)	$ 0.12
Adjustments to Additional Paid in Capital, Stock Subscription				$ 80,574
Debt Instrument, Convertible, Conversion Price (in Dollars per share)		$ 0.168
		$ 144,426	$ 0
Convertible Debt [Member]
Note 7 - Convertible Note Payable - Related Party (Details) [Line Items]
Debt Instrument, Face Amount		1,000,000
Dr. Chen [Member]
Note 7 - Convertible Note Payable - Related Party (Details) [Line Items]
Accounts Payable, Related Parties	$ 144,426			$ 144,426
Chief Executive Officer [Member] | Convertible Debt [Member]
Note 7 - Convertible Note Payable - Related Party (Details) [Line Items]
Debt Instrument, Face Amount		$ 144,426

Note 7 - Convertible Note Pay26

Note 7 - Convertible Note Payable - Related Party (Details) - Convertible Notes Payable - USD ($)	Jul. 31, 2015	Dec. 31, 2015
Note 7 - Convertible Note Payable - Related Party (Details) - Convertible Notes Payable [Line Items]
Shares subscribed (in Shares)	1,200,000	1,200,000
Purchase price		$ 144,426
Purchase premium		80,574
Total	$ 225,000	$ 225,000
(in Shares)
(in Shares)
		$ 80,574
One of the Investors [Member]
Note 7 - Convertible Note Payable - Related Party (Details) - Convertible Notes Payable [Line Items]
Shares subscribed (in Shares)		200,000
Purchase price		$ 24,071
Purchase premium		13,429
Total		$ 37,500
Other Investors [Member]
Note 7 - Convertible Note Payable - Related Party (Details) - Convertible Notes Payable [Line Items]
Shares subscribed (in Shares)		1,000,000
Purchase price		$ 120,355
Purchase premium		67,145
Total		$ 187,500
Dr. Chen [Member]
Note 7 - Convertible Note Payable - Related Party (Details) - Convertible Notes Payable [Line Items]
(in Shares)
	$ (144,426)	$ (144,426)
(in Shares)

Note 8 - Related Party Transa27

Note 8 - Related Party Transactions (Details) - USD ($)	Apr. 01, 2016	Mar. 18, 2016
Note 8 - Related Party Transactions (Details) [Line Items]
Proceeds from Related Party Debt		$ 75,000
Subsequent Event [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Repayments of Related Party Debt	$ 75,000

Note 9 - Corporate Governance28

Note 9 - Corporate Governance and Stock (Details) - shares	Jul. 10, 2015	Jun. 30, 2015	Mar. 31, 2016	Dec. 31, 2015
Corporate Governance And Stock [Abstract]
Preferred Stock, Shares Outstanding			0	0
Preferred Stock, Shares Issued			0	0
Supermajority Voting Rights Percentage of Issued and Outstanding Shares			51.00%
Requirement for Notice to Directors of Special Directors Meeting Time Period	4 hours	24 hours

Note 10 - Subsequent Event (Det

Note 10 - Subsequent Event (Details) - USD ($)	Apr. 25, 2016	Mar. 31, 2016	Mar. 31, 2015
Note 10 - Subsequent Event (Details) [Line Items]
Proceeds from Issuance of Private Placement		$ 250,000	$ 0
Subsequent Event [Member]
Note 10 - Subsequent Event (Details) [Line Items]
Shares Authorized During Period, Private Placement	2,316,667
Proceeds from Issuance of Private Placement	$ 434,375